STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

EHC insider plans sale of 1,020 RSU shares via UBS on NYSE

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Encompass Health Corporation (EHC) Form 144 reports a proposed sale of 1,020 common shares via UBS Financial Services on the NYSE, with an aggregate market value of $126,061.80. The shares were acquired through restricted stock unit vesting in January–February 2023 (individual lots of 218, 290, 233 and 279 shares) and are scheduled for sale on 08/27/2025. The filer certifies no undisclosed material adverse information and provides no reportable sales in the prior three months.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider RSU sales planned; size (~$126k) is small relative to a large-cap issuer and likely immaterial to operations.

The filing documents a notice-of-intent to sell 1,020 shares acquired via RSU vesting in early 2023, executed through UBS on the NYSE. Because the aggregate value is modest, this appears to be a routine liquidity event rather than a signal of company-specific deterioration. The filer affirms no undisclosed material adverse information and reports no other sales in the prior three months.

TL;DR: Compliance disclosure consistent with Rule 144; timing and certification follow standard insider-sale protocols.

The Form 144 provides required details: acquisition method (RSU vesting), acquisition dates, planned sale date, broker, and market value. The signed representation that no material nonpublic information exists aligns with governance expectations when insiders sell. There is no indication of clustered or repeated large insider disposals in this filing.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What shares does the Encompass Health (EHC) Form 144 propose to sell?

The notice lists 1,020 common shares to be sold on the NYSE through UBS Financial Services.

When is the proposed sale date for the shares in the Form 144?

The approximate date of sale is listed as 08/27/2025.

How were the shares acquired that are being sold under Form 144?

All reported shares were acquired via RSU vesting in January–February 2023 (lots of 218, 290, 233, 279).

What is the aggregate market value of the shares to be sold?

The aggregate market value is listed as $126,061.80.

Does the filer report any other sales in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.
Encompass Health Corp

NYSE:EHC

EHC Rankings

EHC Latest News

EHC Latest SEC Filings

EHC Stock Data

11.69B
99.01M
1.41%
96.12%
1.28%
Medical Care Facilities
Services-hospitals
Link
United States
BIRMINGHAM